Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab versus lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma
NL-OMON56205Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elranatamab and lenalidomide in multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jan 2023; status: recruiting.
02
Drugs
elranatamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56205.